🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

This important work has 3 key findings ⭐️Natural history of SMM (including high-risk) is less aggressive than defined by Kyle et al in 2007 ⭐️Risk prediction models dont predict well ⭐️Most progressions to MM are not morbid events (i.e NOT fractures or renal failure) Great job!

Great work on this Raj and George Mellgard! Smouldering myeloma prediction models overestimate progression risk in contemporary patients with SMM, and for those who do progress, most do so without ‘morbid’ progression #mmsm

The incidence of angiosarcoma is increasing in the US with >1000 new cases per year. The overall increase is driven by a higher incidence rate of secondary breast and chest wall angiosarcomas in women, finds retrospective cross-sectional study. ja.ma/443X3nS

Happy to see my first research paper of fellowship is officially in press! So, of course, it’s time for my first ever tweet discussing observations in real-world #Teclistamab patients with #MMSM! (ashpublications.org/bloodadvances/…) A quick thread 1/6

Congratulations to Rainier Patrick Soriano, MD!! We celebrate you today & always. Beautiful speech! @MSHSGeriPalCare #ags24 American Geriatrics Society

HD melphalan + autoHCT in AL amyloidosis following dara-based frontline Rx, N=13, 100-day TRM: 0, 63% MRD -ve at 100 day, 1005 cardiac response. 3-year EFS: 89% Raj Chakraborty Suzanne Lentzsch, MD, PhD Markus Y. Mapara 🇺🇦 #mmsm #bmtsm nature.com/articles/s4140…

Optimal second line treatment for AL Amyloidosis after Daratumuab treatment 👉presented by super-fellow Abdul-Hamid Bazarbachi, MD and his super-mentor Raj Chakraborty at #EHA24 Herbert Irving Comprehensive Cancer Center #mmsm

Teaching is one of the most rewarding parts of my job, and such an honor to receive this award from our fellows ⁦Herbert Irving Comprehensive Cancer Center⁩!

#Myeloma Paper of the Day: International retrospective cohort study to investigate prognostic impact of FISH in 283 patients w/ AL #amyloidosis treated w/ frontline Dara-VCD finds +1q significantly associated w/ worse heme-EFS & lower ≥VGPR rate: pubmed.ncbi.nlm.nih.gov/39197073/. #mmsm

Hot off the press! Coding charts for billing purposes is labor-intensive & repetitive- a perfect application for #ArtificialIntelligence. Here we show how AI can code over half of level 5 charts with a precision of 99%! #EmergencyMedicine Derick Jones Richard Winters MD Mayo Clinic Emergency Medicine

Getting the right combination to break the epigenetic code: nature.com/articles/s4157…. In this new Review, Seda Tolu et al. discuss clinical research focused on maximizing the therapeutic potential of epigenetic agents through combination with other systemic treatments.

Early 6-month mortality in patients with AL #Amyloidosis on frontline Dara-based therapy is 11%, down from 24% in historical controls! Join us Saturday to learn more #ASH24. Grateful to patients & team esp. Raj Chakraborty, Dr. Cowan, and Abdul-Hamid Bazarbachi, MD tinyurl.com/2p9zyvn9

The fog did not lift Flight routed to Las Vegas Ten dollars on red #ASH24 #ASHaiku

Amazing presentation by George Mellgard on early mortality in AL #Amyloidosis in the Dara-VCd era from our multicenter retrospective study. Interestingly, t(11;14), which used to be negative prognostic factor in AL in the Bortezomib-era, is now associated with significantly

Raj Chakraborty George Mellgard Congratulations George Mellgard and Raj Chakraborty on your new predictors for outcome of AL in the era of Dara- what a progress for our patients! Amyloidosis Speakers Bureau AMYLOIDOSIS ALLIANCE Australian Amyloidosis Network Amyloid Academic Consortium

#ASH24 great work by Ross Firestone (who’s basically an assoc prof at Memorial Sloan Kettering Cancer Center despite still being a fellow 😉 ) Regardless of MRD status by NGF (e.g., tumor biology), clear T cell profiles (e.g., immune biology) matter too. This can predict #MMsm PD even if MRD-neg!

Congrats to Amy Song on her first ASH w/ 2 posters! First, on Runx1 and IDH as dynamic markers of hematologic response to IDH inhibitors in myeloid malignancies with Brian Chernak, MD and Aaron Viny. Check out her second tonight at 6PM (No. 4599). #ASH24 Herbert Irving Comprehensive Cancer Center

.Al Garfall Thanks for including a patient advocate on this important LimiTec trial of limited duration Teclistamab for RRMM - It was wonderful to get together in-person with the multi-site team. clinicaltrials.gov/study/NCT05932… #MMsm #ASH24 #HealthTree #myeloma

Rare presentations of systemic AL amyloidosis with diffuse lung involvement - led by Amy Song with Raj Chakraborty. Herbert Irving Comprehensive Cancer Center

onlinelibrary.wiley.com/doi/full/10.11… = the Herbert Irving Comprehensive Cancer Center experience with newly diagnosed myeloma cast nephropathy in the modern era, under the aegis of Raj Chakraborty Suzanne Lentzsch, MD, PhD Divaya Bhutani Markus Y. Mapara 🇺🇦 Jai Radhakrishnan and with second author Metodi Balev! Takeaways below: